Enhancing Cancer Treatment Decisions with Ultrasensitive MRD Testing

Quest Diagnostics, Jesus Izaguirre Carbonell, Thoman Slavin, MRD testing, minimal residual testing, precision tool, biomarker, ctDNA, circulating tumor DNA

Dr. Thomas Slavin breaks down how ultrasensitive MRD testing supports better cancer treatment decisions and enables earlier, more personalized interventions.

Jul 7^th • 19 mins listen

Rethinking How We Track and Treat Cancer

Labcorp, Rebecca Previs, Michelle Green, genomics, ASCO, HER2, HER3, MRD, breast cancer, antibody drug conjugate, ADC, breast cancer, lung cancer, ctDNA, biomarker

HER2, HER3, and MRD: Drs. Previs and Green break down ASCO highlights and what they mean for the future of cancer diagnostics.

Jul 13^th • 19 mins listen

ctDNA Breakthroughs in Mesothelioma Care

Labcorp, Rebecca Previs, Mark Sausen, immunotherapy, mesothelioma, checkpoint blockade, ctDNA, imaging

Exploring immunotherapy and ctDNA innovation in mesothelioma, where molecular monitoring may redefine early cancer detection and treatment.

Nov 3^rd • 15 mins listen

ctDNA in DLBCL: A Blueprint for Better Clinical Trials?

Current clinical characteristics and demographics are not sufficient to capture aggressive disease in clinical trials of newly diagnosed DLBCL. Novel tools, such as measurement of tumor burden via ctDNA, are needed. By : Dr. Matthew Maurer.

Apr 10^th • 7 mins listen